Birmingham Capital Management Co. Inc. AL Sells 30,994 Shares of Pfizer Inc. $PFE

Birmingham Capital Management Co. Inc. AL lessened its stake in Pfizer Inc. (NYSE:PFE) by 19.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 132,249 shares of the biopharmaceutical company’s stock after selling 30,994 shares during the quarter. Pfizer comprises 1.4% of Birmingham Capital Management Co. Inc. AL’s investment portfolio, making the stock its 25th biggest position. Birmingham Capital Management Co. Inc. AL’s holdings in Pfizer were worth $3,206,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. acquired a new stake in shares of Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth $29,000. Finally, Horizon Financial Services LLC acquired a new stake in Pfizer in the first quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.2%

Shares of NYSE PFE opened at $24.52 on Monday. The firm has a 50 day moving average price of $24.89 and a two-hundred day moving average price of $24.11. The stock has a market cap of $139.38 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.